# Zeno Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zeno-biotech

- Industry: Biotechnology
- Headquarters: Changshu, China
- Website: www.zenobiotech.cn
- Total disclosed funding: $1.6M
- Latest round: Angel (Mar 14, 2022)
- Investors on record: 2

## About

Zeno Biotech, based in China, specializes in the production of human milk oligosaccharides (HMOs) and microbial-based natural pigments, leveraging advanced fermentation technology for high-purity products.Founded in 2020 in Changshu, China, Zeno Biotech focuses on developing human milk oligosaccharides, specifically 2'-fucosyllactose (2'-FL). The company has not undergone any significant pivots and operates independently without mentions of subsidiaries. In March 2022, Zeno Biotech raised CNY 10 million in an Angel funding round from CITIC Capital Holdings and Hainan Jiacheng Venture Capital, marking its first deal and bringing its total funding to CNY 10 million.Zeno Biotech specializes in producing human milk oligosaccharides (HMOs), particularly 2'-fucosyllactose (2'-FL), the most abundant HMO in human milk. Utilizing proprietary engineered strains, the company achieves over 95% purity in its products. HMOs enhance gut health, benefiting both infants and adults. Zeno's primary markets extend beyond China, reaching clients in North America and Europe, responding to the increasing demand for innovative nutritional supplements.Zeno Biotech's revenue is derived from B2B transactions, supplying high-value HMO products to food manufacturers, infant formula producers, and dietary supplement companies. The firm forms partnerships with industry players to enhance product integration and nutritional value. Its sales structure promotes bulk orders with volume-based pricing agreements. Additionally, Zeno plans to expand production capacity to nearly 400 tons by launching a new facility in the first half of 2024, aiming to meet rising global demand, particularly in infant nutrition and gut health solutions.In March 2022, Zeno Biotech secured CNY 10 million in Angel funding to advance the commercialization of human milk oligosaccharides and microbial-based natural pigments. The company plans to introduce new products that leverage its fermentation technology and is targeting expansions into North American and European markets by mid-2024. This funding will support the development of these initiatives, strengthening its position in the nutritional supplement sector.

## Funding rounds

- Angel, Mar 14, 2022, $1.6M — CITIC Capital Holdings, Hainan Jiacheng Venture Capital

## Investors

- CITIC Capital Holdings (https://capitalatlas.ai/funds/citic-capital-holdings) — Angel
- Hainan Jiacheng Venture Capital — Angel